Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma

You may be eligible if

• DISEASE CHARACTERISTICS
• Archival tumor sample must express IL13Rα2 by immuno-histochemistry (IHC) analysis
• Must have prior histologic diagnosis of supratentorial malignant glioma (Grade 3 or 4), including glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, or mixed oligoastrocytoma (excludes glioma of unknown grade). Patients with clinical/radiographic diagnosis of malignant glioma may be registered pending histologic confirmation.
• Must have undergone prior surgical resection and received external beam radiotherapy with at least 48 Gy tumor dose, completed at least 8 weeks prior to study
• Must have recurrent or progressive supratentorial malignant glioma compared with a previous diagnostic study
• Baseline tumor measured within 2 weeks prior to study entry
• Stereotactic biopsy at study entry must confirm the presence of glioma (malignant, unless previously documented)
• Recurrent or progressive tumor must have a solid contrast-enhancing region at least 1.0 cm and no more than 5.0 cm in maximum diameter. One satellite lesion is permitted if separated by 3 cm or less from the primary mass.
• PATIENT CHARACTERISTICS
• Age 18 and over
• Karnofsky Performance Score of at least 70
• Absolute neutrophil count at least 1500/mm\^3
• Hemoglobin at least 10 gm/dL
• Platelet count at least 100,000/mm\^3
• PT and aPTT within institutional limit of normal
• Must be candidate for re-operation
• Must have recovered from toxicity of prior therapy. Minimum intervals required: at least 6 months after approved intratumoral chemotherapy (e.g. carmustine wafer), at least 6 weeks after nitrosourea-containing chemotherapy, at least 4 weeks after any investigational agent or any other cytotoxic chemotherapy, at least 2 weeks after vincristine or non-cytotoxic chemotherapy
• Must practice an effective method of birth control during the study
• Must understand the investigational nature of this study and its potential risks and benefits, and sign an approved written informed consent prior to performance of any study-specific procedure
• No patients with tumor crossing the midline (tumor involving corpus callosum is permitted if not crossing midline), more than two foci of tumor, or non-parenchymal tumor dissemination (e.g. subependymal or leptomeningeal)
• No patients with impending herniation (e.g. midline shift greater than 1.0 cm), uncontrolled seizures, or requirement for immediate palliative treatment
• No patients who have received localized therapy for glioma, e.g. focal single-fraction radiotherapy, brachytherapy, or intracerebral infusion of chemotherapy or cytotoxin
• No patients who are receiving any concurrent chemotherapy or any other investigational agent (corticosteroids are permitted)
• No patients with a known allergy to iodine or to contrast medium that may be utilized in scans required by this protocol
• Female patients must not be pregnant or breast-feeding
• No patients unwilling or unable to follow protocol requirements